• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

The Impact of CRM Diseases in the US: Burden, Prevalence, and Obesity

Opinion
Video

A panel of experts examines the impact of cardiometabolic diseases in the United States, focusing on their burden, prevalence, and relationship to obesity.

Video content above is prompted by the following:

  • What is the clinical and economic burden of Cardiorenal Metabolic Disease (CRM) conditions such as type 2 diabetes, chronic kidney disease, cardiovascular disease and heart failure in the United States?
  • How do CRM conditions affect patient quality of life and clinical outcomes?
  • How do these conditions impact healthcare resource utilization?
  • The CDC has announced that over 42% of adults have obesity; what role does obesity play in the prevalence of CRM conditions in the United States?
  • Is this your experience in your practice?

This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.

Related Videos
Dr Carla Nester
AJMC interview with Ali Shan Hafeez and Dr Abdul Rafae Faisal | Background image credit: ipopba - stock.adobe.com
2 experts in this video
2 experts in this video
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.